Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Orthocell's Remplir nerve wrap hit its highest U.S. monthly sales since launch in October 2026, signaling growing market traction.
Australian medical device maker Orthocell Ltd recorded its strongest month of U.S. sales for its Remplir collagen nerve wrap since the product launched, with 92 units sold in October 2026, according to a company announcement.
Remplir is an FDA-cleared collagen nerve wrap engineered to support the repair and protection of peripheral nerves. The device is designed and manufactured in Australia, and Orthocell has been positioning it as an emerging category leader in key international markets.
Read more Renue Hawaii Rolls Out Institutional Carpet Care Program for Resort Season →
The October milestone represents a measurable inflection point for the company's U.S. commercial strategy. Peripheral nerve repair is a specialized surgical segment, and consistent monthly volume growth in the U.S. market typically signals deeper penetration among surgeons and hospital systems rather than one-time adoption.
Orthocell's ability to manufacture the device domestically in Australia while achieving FDA clearance and meaningful U.S. traction places it in a competitive position relative to other international medtech firms seeking a foothold in American surgical markets. The company has not disclosed cumulative U.S. sales figures or revenue breakdowns tied to the October performance.
Continue reading at All Financial Services & Investing.
